切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2024, Vol. 18 ›› Issue (09) : 863 -867. doi: 10.3877/cma.j.issn.1674-0785.2024.09.011

综述

慢性肝病肝纤维化无创诊断的研究进展
李浩1, 陈棋帅2, 费发珠1, 张宁伟1, 李元东1, 王硕晨1, 任宾1,()   
  1. 1.810012 青海西宁,青海大学附属医院肝胆胰外科
    2.810012 青海西宁,青海大学附属医院肿瘤外科
  • 收稿日期:2024-08-19 出版日期:2024-09-15
  • 通信作者: 任宾
  • 基金资助:
    2021 年度青海省“昆仑英才·高端创新创业人才”项目

Progress in noninvasive diagnosis of liver fibrosis in chronic liver disease

Hao Li1, Qishuai Chen2, Fazhu Fei1, Ningwei Zhang1, Yuandong Li1, Shuochen Wang1, Bin Ren1,()   

  1. 1.Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining 810012, China
    2.Department of Oncology Surgery, Affiliated Hospital of Qinghai University, Xining 810012, China
  • Received:2024-08-19 Published:2024-09-15
  • Corresponding author: Bin Ren
引用本文:

李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.

Hao Li, Qishuai Chen, Fazhu Fei, Ningwei Zhang, Yuandong Li, Shuochen Wang, Bin Ren. Progress in noninvasive diagnosis of liver fibrosis in chronic liver disease[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(09): 863-867.

慢性肝病可由多种因素引起,如病毒性、酒精、非酒精性脂肪性肝病、自身免疫性、药物性肝损伤和遗传因素等。肝维化是各种慢性肝病的一种重要病理性修复反应,与肝脏肿瘤和死亡密切相关。尽管肝组织活检是诊断肝纤维化的金标准,但有创且局限。当前的组织病理学纤维化分期系统对纤维化监测不够敏感。因此,对肝纤维化进行早期和无创的诊断以及准确的分期,是治疗和控制肝纤维化进展的关键。文章综述了慢性肝病患者肝纤维化无创性诊断方法的研究进展。

Chronic liver disease can be caused by a variety of factors, such as viral disease,alcohol and non-alcoholic fatty liver disease, autoimmune disorder, drug-induced liver injury, and genetic factors. Liver fibrosis is an important pathological repair reaction to various chronic liver diseases, which is closely related to the development of liver tumors and death. Although liver biopsy is the gold standard for the diagnosis of liver fibrosis, it is invasive and has limited use. The current histopathological fibrosis staging system is not sensitive enough to fibrosis monitoring. Therefore, early and non-invasive diagnosis and accurate staging of liver fibrosis are the key to treating and controlling the progression of fibrosis. This article reviews the progress in research of non-invasive diagnostic methods for liver fibrosis in patients with chronic liver disease.

24
鄂维建, 芦永良, 祁秉民, 等. 血清巨噬细胞极化相关因子与多房棘球蚴病肝纤维化的相关性分析 [J]. 临床肝胆病杂志, 2021,37(12): 2813-2818.
25
Gatselis NK, Tornai T, Shums Z, et al. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients [J].World J Gastroenterol, 2020, 26(34): 5130-5145.
26
Wang J, Sun X, Wei S, et al. Noninvasive models for the prediction of liver fibrosis in patients with chronic hepatitis B [J]. BMC Gastroenterol, 2024, 24(1): 183.
27
郝岸华, 杜忠彩, 周林, 等. 慢性乙型肝炎患者肝脏硬度检测和S指数变化及评估肝纤维化程度应用价值探讨 [J]. 实用肝脏病杂志,2023, 26(5): 630-633.
28
Ozturk A, Olson MC, Samir AE, et al. Liver fibrosis assessment: MR and US elastography [J]. Abdom Radiol(NY), 2022, 47(9): 3037-3050.
29
曹建彪, 陈永平, 成军, 等. 瞬时弹性成像技术(TE)临床应用专家共识(2015 年) [J/OL].中国肝脏病杂志(电子版), 2015, 7(2):1218.
30
Lorée H, Bastard C, Miette V, et al. Vibration-guided transient elastography:a novel Fibroscan® examination with improved guidance for liver stiffness measurement [J]. Ultrasound Med Biol, 2020, 46(9):2193-2206.
31
武永萍, 魏占芳, 石栓柱, 等. 瞬时弹性超声成像在评价乙型肝炎肝纤维化严重程度中的价值 [J]. 肝脏, 2019, 24(8): 905-907.
32
尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022 年版) [J].实用肝脏病杂志, 2023, 26(3): 457-478.
33
王民, 刘婷婷, 王晓明, 等. 评价声辐射力脉冲成像诊断非酒精性脂肪性肝病纤维化的效能 [J]. 临床和实验医学杂志, 2018, 17(2):124-128.
34
Bui HH, Vo VH, Nguyen CD, et al. Diagnostic performance of acoustic radiation force impulse imaging in evaluating liver fibrosis in patients with chronic hepatitis B infection: A cross-sectional study [J].Indian Radiol Imaging, 2022,32 (3): 287-293.
35
Zhang X, Huang P, Wang X, et al. Development and validation of a non-invasive model for diagnosing HBV-related liver cirrhosis [J].Clin Chim Acta, 2021, 523: 525-531.
36
何桥, 原文聪, 樊海宁, 等. 弹性成像联合血清学诊断慢性乙型肝炎肝纤维化的研究现状 [J]. 临床肝胆病杂志, 2021, 37(12): 2914-2918.
37
车艳玲, 蒋敏, 徐皓煊, 等. 超声剪切波弹性成像在慢性乙型肝炎肝纤维化诊断中的应用 [J]. 中国临床保健杂志, 2022, 25(5): 682-685.
38
韩磊, 邬超, 张同, 等. 影像技术在肝纤维化诊断应用中的研究进展 [J]. 中国医学装备, 2023, 20(12): 196-200.
39
Jhaveri KS, Hosseini-Nik H, Sadoughi N,et al. The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis [J]. Eur Radiol. 2019, 29(2): 1039-1047.
40
Fu F, Li X, Chen C, et al. Non-invasive assessment of hepatic fibrosis: comparison of MR elastography to transient elastography and intravoxel incoherent motion diffusion-weighted MRI [J]. Abdom Radiol (NY), 2020, 45(1): 73-82.
41
Park HS, Choe WH, Han HS, et al. Assessing significant fibrosis using imaging -based elastography in chronic hepatitis B patients:Pilot study[J]. World J Gastroenterol, 2019, 25(25): 3256-3267.
42
沈萍, 马盛元, 许华宇, 等. MR 弹性成像对慢性乙型肝炎肝纤维化的诊断价值 [J]. 中华放射学杂志, 2019, 53(8): 710-714.
43
Jiang H, Chen J, Gao R, et al. Liver fibrosis staging with diffusionweighted imaging: a systematic review and meta-analysis [J]. Abdom Radiol(NY), 2017, 42(2): 490-501.
1
彭颖. 慢性肝病进展的危险因素及预测评估模型 [D]. 重庆: 中国人民解放军陆军军医大学, 2023.
2
朱红梅, 王勤英. 非酒精性脂肪性肝病肝纤维化的诊断和治疗进展 [J]. 临床肝胆病杂志, 2020, 36(1): 178-181.
3
Li Y, Yang Y, Li Y, et al. Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis [J]. J Int Med Res,2021, 49(11): 03000605211055378.
4
Long MT, Gandhi S, Loomba R. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease [J].Metabolism, 2020, 111S: 154259.
5
Wei YB, Jang CH. Visualization of cholylglycine hydrolase activities through nickel nanoparticle-assisted liquid crystal cells [J]. Sensors and Actuators, 2017, B239(FEB): 1268-1274.
6
李松鹏, 景红艳. 甘胆酸(CG)在肝炎检测中的应用价值 [J]. 中外医疗, 2018, 37(17): 190-191+198.
7
Aleknavičiūtė-Valienė G, Banys V. Clinical importance of laboratory biomarkers in liver fibrosis [J]. Biochem Med (Zagreb), 2022, 32(3):030501.
8
魏莎, 陈晰, 章臻翊, 等. 肝纤维化的早期血清标志物研究进展 [J].实用预防医学, 2024, 31(2): 252-257.
9
王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展 [J/OL]. 中华临床医师杂志(电子版), 2024, 18(7):677-681.
10
倪雅惠, 秦东媛, 王琳. 肝硬化患者血清总胆汁酸、高尔基体蛋白73 及糖类抗原19-9 的水平变化及其临床意义 [J]. 中国普通外科杂志, 2024, 33(2): 305-310.
11
Yao M, Wang L, Leung PSC, et al.The clinical significance of GP73 in immunologically mediated chronic liver diseases:experimental data and literature review [J]. Clin Rev Allergy Immunol, 2018, 54(2): 282-294.
12
马杨青, 范海纳, 孙鑫, 等. 高尔基体蛋白73(GP73)对慢性肝病的诊断价值 [J]. 临床肝胆病杂志, 2023, 39(8): 1999-2004.
13
Wang X, He Y, Mackowiak B, et al. MicroRNAs as regulators,biomarkers and therapeutic targets in liver diseases [J]. Gut, 2021,70(4): 784-795.
14
黄璐, 吴有斌, 倪毅然, 等. miRNAs 在肝纤维化中的作用机制 [J].协和医学杂志, 2023, 14(6): 1251-1257.
15
Matsumoto Y, Itami S, Kuroda M, et al. MiR-29a assists in preventing the activation of Human stellate cells and promotes recovery from liver fibrosis in mice [J]. Mol Ther, 2016, 24: 1848-1859.
16
Alarcon CR, Lee H, Goodarzi H, et al. N6-methyl-adenosine marks primary micro-RNAs for processing [J]. Nature, 2015, 519: 482-485.
17
Tadokoro T, Morishita A, Masaki T. Diagnosis and therapeutic management of liver fibrosis by microRNA [J]. Int J Mol Sci, 2021,22(15): 8139.
18
Song L,Chen TY, Zhao XJ, et al. Pterostilbene prevents hepatocyte epithelial -mesenchymal transition in fructose-induced liver fibrosis through suppressing miR-34a/Sirt1/p53 and TGF-beta1/smads signalling [J]. Br J Pharmacol, 2019, 176: 1619-1634.
19
Tian XF, Ji FJ, Zang HL, et al. Activation of the miR-34 a/ SIRT1/p53 signaling pathway contributes to the progress of liver fibrosis via inducing apoptosis in hepatocytes but not in HSCs [J]. PLoS One,2016, 11: e158657.
20
Lee CH, Seto WK, Lui DT, et al. Circulating thrombospondin-2 as a novel fibrosis biomarker of nonalcoholic fatty liver disease in type 2 diabetes [J]. Diabetes Care, 2021, 44(9): 2089-2097.
21
王伟, 马玉萍, 马海婷, 等. 血清M2BPGi 联合MRI-DWI 预测丙型肝炎患者肝纤维化的临床价值 [J]. 实用医学杂志, 2018, 34(2):293-296+300.
22
Baudi I, Inoue T, Tanaka Y. Novel biomarkers of hepatitis B and hepatocellular carcinoma: clinical significance of HBcrAg and M2BPGi [J]. Int J Mol Sci, 2020, 21(3): 949.
23
Ito K, Murotani K, Nakade Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis:a meta-analysis [J]. J Gastroenterol Hepatol, 2017, 32(12): 1922-1930.
[1] 任新平, 郑丽丽, 冯梅晶, 肖俊飞, 林艳艳, 詹维伟. 高帧频超声造影对慢性肝病患者≤3 cm肝局灶性病变定性诊断的应用价值[J/OL]. 中华医学超声杂志(电子版), 2023, 20(11): 1119-1124.
[2] 高建松, 陈晓晓, 冯婷, 包剑锋, 魏淑芳, 潘林. 基于超声瞬时弹性成像的多参数决策树模型评估慢性乙型肝炎患者肝纤维化等级[J/OL]. 中华医学超声杂志(电子版), 2023, 20(09): 923-929.
[3] 骆云凯, 鄢曹鑫, 张宣宣, 李如梅, 王文倩, 洪行行, 夏斌, 邹伟璞, 张珊珊, 陈剑. 声触诊弹性成像检测脾硬度对诊断慢性乙肝肝纤维化程度的应用价值[J/OL]. 中华医学超声杂志(电子版), 2022, 19(11): 1232-1237.
[4] 李沁园, 董常峰, 冯程, 李志艳, 刘李, 何秉昊, 姜伟, 田文硕, 杨帅. 基于弹性成像多模态法评估慢性乙型肝炎肝纤维化程度[J/OL]. 中华医学超声杂志(电子版), 2022, 19(09): 976-982.
[5] 施娜, 邱文倩, 何丹青, 张超学, 毛萍, 杨艳婷. 瞬时弹性成像评价慢性乙型肝炎患者抗病毒治疗的效果[J/OL]. 中华医学超声杂志(电子版), 2022, 19(05): 428-433.
[6] 李敏, 杨世英, 高晓琴, 周丹, 唐筱, 张立婷. 维生素A与慢性肝病相关性研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(02): 65-70.
[7] 张麒, 马臻. 丙型肝炎肝纤维化进展影响因素及标志物研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(01): 1-6.
[8] 李炜, 段英, 庄立伟, 邢卉春. 慢性肝病合并内源性眼内炎五例并文献复习[J/OL]. 中华实验和临床感染病杂志(电子版), 2021, 15(02): 138-143.
[9] 杨皖东, 肖春华, 普慧敏, 李永峰, 李鸿, 杨薇, 沈燕, 丁世兰. 剪切波弹性成像在供肝评估中的临床应用[J/OL]. 中华移植杂志(电子版), 2020, 14(04): 220-224.
[10] 季瑞冬, 卢振权, 罗兵锋, 侯健, 董汝男, 廖苏才, 罗光彦, 梁伟, 张可可, 郭敏姗, 卢捷娜, 吴旻, 杨伟洪. 无创诊断方法在原发性醛固酮增多症分型诊断中的应用及研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(02): 186-191.
[11] 江浩, 余宏圣, 杨碧兰, 阿布都克尤木·斯马依, 吴斌, 杨逸冬. 基于列线图模型对慢性乙型肝炎合并肝脏脂肪变性患者并发晚期肝纤维化的临床预测[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 114-120.
[12] 丁茜, 李振, 王思宁, 赵连晖, 王广川, 张春清. 人肝窦内皮细胞中α1肾上腺素能受体亚型表达的初步实验研究[J/OL]. 中华消化病与影像杂志(电子版), 2022, 12(02): 98-101.
[13] 李明凯, 吴晓瑛, 吴斌. 磁共振弹性成像技术在慢性肝病的临床应用研究进展[J/OL]. 中华消化病与影像杂志(电子版), 2021, 11(03): 126-131.
[14] 刘志强, 窦项洁, 刘白露, 董晓萌, 鲍俊宇. 银杏达莫注射液对大鼠肝缺血再灌注损伤的保护作用机制研究[J/OL]. 中华诊断学电子杂志, 2022, 10(04): 259-265.
[15] 张娜, 鲁志宏, 张盛军, 陈启众, 俞永涛, 陈申思, 钱海权, 刘轲. 腹腔镜袖状胃切除术治疗肥胖合并非酒精性脂肪肝患者肝纤维化的短期疗效分析[J/OL]. 中华肥胖与代谢病电子杂志, 2023, 09(04): 261-266.
阅读次数
全文


摘要